

**Second Quarter And Half Year Financial Statements Announcement For The Period Ended 30 September 2015**  
**(In accordance with International Financial Reporting Standards)**

**PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS**

**1(a) An income statement (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year.**

**Consolidated Income Statement for the second quarter and half year ended 30 September 2015**

	Note	The Group					
		2nd Quarter Ended			Half Year Ended		
		30-Sep-15	30-Sep-14	Change	30-Sep-15	30-Sep-14	Change
		US\$'000	US\$'000	%	US\$'000	US\$'000	%
<b>Revenue</b>							
Product revenue	A	56,704	68,864	(18)	117,236	139,332	(16)
Licensing and royalties revenue		3,306	5,922	(44)	9,801	15,664	(37)
<b>Total revenue</b>		<b>60,010</b>	<b>74,786</b>	(20)	<b>127,037</b>	<b>154,996</b>	(18)
<b>Total cost of sales</b>		(17,762)	(20,886)	(15)	(33,761)	(41,366)	(18)
<b>Gross profit</b>		<b>42,248</b>	<b>53,900</b>	(22)	<b>93,276</b>	<b>113,630</b>	(18)
<b>Operating expenses</b>							
Sales and marketing expenses	B	(19,875)	(25,959)	(23)	(40,164)	(52,883)	(24)
General and administrative expenses	C	(8,080)	(9,452)	(15)	(15,915)	(20,104)	(21)
Research and development expenses	D	(5,583)	(8,259)	(32)	(10,205)	(15,309)	(33)
		(33,538)	(43,670)	(23)	(66,284)	(88,296)	(25)
<b>Profit from operations</b>	E	<b>8,710</b>	<b>10,230</b>	(15)	<b>26,992</b>	<b>25,334</b>	7
Other income/(expenses), net	F	5,044	(137)	NM	3,961	(398)	NM
Financial income	G	1,825	1,815	1	3,871	3,546	9
Financial expenses	H	(3,266)	(3,454)	(5)	(6,617)	(6,866)	(4)
<b>Profit before exceptional and non-operating items</b>		<b>12,313</b>	<b>8,454</b>	46	<b>28,207</b>	<b>21,616</b>	30
Amortisation of customer lists and patents		(4,524)	(4,563)	(1)	(9,157)	(9,199)	(0)
Exceptional items - restructuring of operations		(3,206)	510	NM	(3,960)	510	NM
<b>Profit before tax</b>		<b>4,583</b>	<b>4,401</b>	4	<b>15,090</b>	<b>12,927</b>	17
Income tax	I	(573)	522	NM	(1,619)	1,867	NM
<b>Net profit for the period</b>		<b>4,010</b>	<b>4,923</b>	(19)	<b>13,471</b>	<b>14,794</b>	(9)
<b>Attributable to:</b>							
Equity holders of the Company		4,010	4,923		13,471	14,794	
<b>Earnings per share (US cent)</b>							
<b>Before exceptional items</b>	(see footnotes)						
Basic		0.43	0.26		1.04	0.84	
Diluted		0.43	0.26		1.03	0.84	
<b>After exceptional items</b>							
Basic		0.24	0.29		0.80	0.87	
Diluted		0.24	0.29		0.80	0.86	

NM - Not meaningful

## Consolidated Statement of Comprehensive Income

The Group						
2nd Quarter Ended			Half Year Ended			
30-Sep-15	30-Sep-14	Change	30-Sep-15	30-Sep-14	Change	
US\$'000	US\$'000	%	US\$'000	US\$'000	%	
<b>Net profit for the period</b>	<b>4,010</b>	<b>4,923</b>	(19)	<b>13,471</b>	<b>14,794</b>	(9)
<b>Other comprehensive income:</b>						
Exchange differences on translation of financial statements of foreign subsidiaries	(36,653)	(23,912)	53	(32,549)	(2,058)	NM
<b>Total comprehensive income</b>	<b>(32,643)</b>	<b>(18,989)</b>		<b>(19,078)</b>	<b>12,736</b>	

### Attributable to:

Equity holders of the Company

(32,643)	(18,989)	(19,078)	12,736
----------	----------	----------	--------

### Footnotes

<sup>1</sup> Weighted average ordinary shares issued ('000)

1,685,808	1,698,679	1,683,710	1,698,060
-----------	-----------	-----------	-----------

<sup>2</sup> Weighted average ordinary shares and equivalents outstanding ('000)

1,688,277	1,709,701	1,686,519	1,710,438
-----------	-----------	-----------	-----------

Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares.

Diluted earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares adjusted for the effects of dilutive options.

## Notes to the Income Statements

### A Product revenue

	The Group			
	2nd Quarter Ended		Half Year Ended	
	30-Sep-15	30-Sep-14	30-Sep-15	30-Sep-14
	US\$'000	US\$'000	US\$'000	US\$'000
Critical care products	3,988	3,655	7,744	8,031
Interventional cardiology products	49,038	61,303	102,542	122,998
Cardiac diagnostic	3,678	3,906	6,950	8,303
	<u>56,704</u>	<u>68,864</u>	<u>117,236</u>	<u>139,332</u>

B Sales and marketing expenses decreased 23% to US\$19.9 million for the quarter ended 30 September 2015 compared to US\$26.0 million for the quarter ended 30 September 2014 mainly due to reduced payroll related expenses, marketing, exhibition and travelling related expenses.

C General and administrative expenses decreased 15% to US\$8.1 million from US\$9.5 million in the corresponding quarter of last year mainly due to lower professional fee and share-based payment expenses.

D Research and development expenses decreased 32% to US\$5.6 million compared to US\$8.3 million in the quarter ended 30 September 2014 mainly due to lower clinical trial expenses.

E Profit from operations is determined after (charging)/crediting the following:

	The Group			
	2nd Quarter Ended		Half Year Ended	
	30-Sep-15	30-Sep-14	30-Sep-15	30-Sep-14
	US\$'000	US\$'000	US\$'000	US\$'000
Depreciation of property, plant and equipment	(1,423)	(1,995)	(2,840)	(3,712)
Amortisation of intangible assets (excluding customer lists and patents)	(472)	(247)	(952)	(506)
Realisation of deferred revenue	1,501	1,342	3,526	3,940
(Allowance for)/write-back of doubtful trade debts, net	(311)	1,206	1,108	516
Write-back for doubtful non-trade debts, net	2	3	5	6
Inventories write-down, net	(550)	(1,607)	(864)	(4,078)
Provision for warranty, net	(3)	(12)	(5)	(33)
(Provision)/Reversal for sales return	(40)	(237)	16	(492)
Impairment of property, plant and equipment	-	-	(58)	66
Intangible assets written off	-	(15)	-	(15)
Property, plant and equipment written off	8	(18)	(7)	(73)
Inventories written off	(253)	(122)	(1,232)	(317)
(Loss)/gain on disposal of property, plant and equipment	(2)	-	(7)	1
Foreign exchange gains/(losses)	5,097	(127)	4,073	(376)

F Other income/(expenses), net

	The Group			
	2nd Quarter Ended		Half Year Ended	
	30-Sep-15	30-Sep-14	30-Sep-15	30-Sep-14
	US\$'000	US\$'000	US\$'000	US\$'000
(Loss)/gain on disposal of property, plant and equipment, net	(2)	-	(7)	1
Foreign exchange gain/(loss), net	5,097	(127)	4,073	(376)
Other miscellaneous expenses, net	(51)	(10)	(105)	(23)
	<u>5,044</u>	<u>(137)</u>	<u>3,961</u>	<u>(398)</u>

Other operating expenses for the quarter was mainly the exchange gain from the appreciation of JPY and EUR against USD during the period.

G Financial income

	2nd Quarter Ended		Half Year Ended	
	30-Sep-15	30-Sep-14	30-Sep-15	30-Sep-14
	US\$'000	US\$'000	US\$'000	US\$'000
Interest income				
- bank balances	217	340	438	709
- fixed deposits	1,589	1,455	3,395	2,797
- others	19	20	38	40
	<u>1,825</u>	<u>1,815</u>	<u>3,871</u>	<u>3,546</u>

H Financial expenses

	2nd Quarter Ended		Half Year Ended	
	30-Sep-15	30-Sep-14	30-Sep-15	30-Sep-14
	US\$'000	US\$'000	US\$'000	US\$'000
Interest expense				
- long term loan	(403)	(282)	(810)	(477)
- notes payable	(2,856)	(3,160)	(5,793)	(6,356)
- others	(7)	(12)	(14)	(33)
	<u>(3,266)</u>	<u>(3,454)</u>	<u>(6,617)</u>	<u>(6,866)</u>

I Income tax

Income tax for the current quarter and the half year ended 30 September 2015 includes mainly corporate income tax expenses.

**1(b)(i) A balance sheet (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.**

**Consolidated Balance Sheets as at 30 September 2015**

	Note	The Group		The Company	
		30-Sep-15	31-Mar-15	30-Sep-15	31-Mar-15
		US\$'000	US\$'000	US\$'000	US\$'000
<b>Non-Current Assets</b>					
Property, plant and equipment		81,177	86,289	-	-
Investment in subsidiaries		-	-	584,716	584,716
Other investments	A	30,844	28,836	30,844	28,836
Intangible assets		125,090	134,875	13,177	12,199
Deposit pledged for bank loan		1,049	1,092	-	-
Goodwill		424,682	439,576	52,579	52,579
Deferred tax assets		255	258	-	-
Long term loan to a third party		1,500	1,500	-	-
Long term loans to subsidiaries		-	-	57,039	56,616
<b>Current Assets</b>					
Inventories	B	45,751	44,474	-	-
Trade receivables	C	62,632	73,121	-	-
Other receivables		3,495	4,059	1,180	-
Deposits and prepayments	D	18,941	15,058	1,330	523
Due from subsidiaries (non-trade)		-	-	15,261	13,303
Due from subsidiaries (trade)		-	-	5,762	7,042
Short term loan to a third party		500	500	-	-
Deposits pledged for bank loans		44,090	47,793	-	-
Cash and cash equivalents		523,686	518,253	288,520	298,656
		699,095	703,258	312,053	319,524
Less:					
<b>Current Liabilities</b>					
Trade payables		8,557	6,605	-	-
Other payables		17,467	18,939	560	768
Accruals	E	23,140	26,702	1,666	2,291
Provisions		2,603	2,747	-	-
Due to subsidiaries (non-trade)		-	-	10,076	18,413
Provision for income tax		6,204	6,845	389	23
Deferred revenue, current portion	F	1,849	1,678	-	-
Finance lease liabilities, current portion		18	19	-	-
Borrowings	G	41,303	41,433	39,000	41,046
Contingent consideration		2,410	2,410	2,410	2,410
		103,551	107,378	54,101	64,951
<b>Net Current Assets</b>		595,544	595,880	257,952	254,573
Less:					
<b>Non-Current Liabilities</b>					
Deferred tax liabilities		13,669	15,220	-	-
Deferred revenue, non-current portion	F	903	1,561	-	-
Finance lease liabilities, non-current portion		48	60	-	-
Borrowings	G	243,699	254,260	205,612	211,819
Other payable - non current		63	78	63	78
Pension funds		2,774	2,701	-	-
		261,156	273,880	205,675	211,897
		998,985	1,014,426	790,632	777,622
<b>Capital and Reserves</b>					
Share capital		118	117	118	117
Share premium		750,266	746,042	750,266	746,042
Treasury shares		(54,692)	(54,692)	(54,692)	(54,692)
Translation reserves		13,078	45,627	-	-
Other reserves		18,937	19,525	17,891	18,479
Accumulated profits		271,278	257,807	77,049	67,676
		998,985	1,014,426	790,632	777,622
<b>Net assets values</b>					
Net assets per share (US cent)		59.16	60.36	46.82	46.27
Footnote					
Number of shares in issue at end of period ('000)		1,688,550	1,680,706	1,688,550	1,680,706

Net assets per share is calculated by dividing the net assets by the number of shares in issue as at the balance sheet date.

## Notes to the Balance Sheets

A	<u>Other investments</u>	<u>The Group</u>		<u>The Company</u>	
		<u>30-Sep-15</u> US\$'000	<u>31-Mar-15</u> US\$'000	<u>30-Sep-15</u> US\$'000	<u>31-Mar-15</u> US\$'000
	Available-for-sale				
	Unquoted convertible bonds, at cost	4,500	3,000	4,500	3,000
	Unquoted shares, at cost	15,344	14,836	15,344	14,836
		<u>19,844</u>	<u>17,836</u>	<u>19,844</u>	<u>17,836</u>
	Held for trading				
	Unquoted equity warrants, at cost	11,000	11,000	11,000	11,000
		<u>30,844</u>	<u>28,836</u>	<u>30,844</u>	<u>28,836</u>
B	<u>Inventories</u>			<u>The Group</u>	
				<u>30-Sep-15</u>	<u>31-Mar-15</u>
				US\$'000	US\$'000
	Finished goods			25,511	22,636
	Work-in-progress			4,402	5,225
	Sub-assemblies			4,119	4,192
	Raw materials			10,914	11,507
	Goods-in-transit			805	914
	Total inventories at lower of cost and net realisable value			<u>45,751</u>	<u>44,474</u>
C	<u>Trade receivables</u>			<u>The Group</u>	
				<u>30-Sep-15</u>	<u>31-Mar-15</u>
				US\$'000	US\$'000
	Trade receivables			67,591	79,075
	Less: allowance for doubtful trade debts			(4,959)	(5,954)
				<u>62,632</u>	<u>73,121</u>
	Movements in allowance for doubtful trade debts during the period were as follows:				
	At beginning of year			5,954	8,514
	Reversal for the year			(1,108)	(449)
	Written off against allowance			(33)	(555)
	Translation differences			146	(1,556)
	At end of year			<u>4,959</u>	<u>5,954</u>
D	<u>Deposits and prepayments</u>			<u>The Group</u>	
				<u>30-Sep-15</u>	<u>31-Mar-15</u>
				US\$'000	US\$'000
	Deposits	439	881	-	162
	Prepayments	18,502	14,177	1,330	361
		<u>18,941</u>	<u>15,058</u>	<u>1,330</u>	<u>523</u>
E	<u>Accruals</u>			<u>The Group</u>	
				<u>30-Sep-15</u>	<u>31-Mar-15</u>
				US\$'000	US\$'000
	Accrued operating expenses			11,842	15,034
	Accrued payroll expense			11,122	11,402
	Accrued purchases			176	266
				<u>23,140</u>	<u>26,702</u>
F	<u>Deferred revenue</u>				
	This relates to the deferred revenue from the cardiac diagnostic business which will be realised over the service contracts period.				
G	<u>Loans and borrowings</u>			<u>The Group</u>	
				<u>30-Sep-15</u>	<u>31-Mar-15</u>
				US\$'000	US\$'000
	Cross-border loans			39,000	39,000
	Medium terms notes			208,718	216,708
	Construction loan			37,284	39,985
				<u>285,002</u>	<u>295,693</u>

**1(b)(ii) Aggregate amount of group's borrowings and debt securities.**

**Amount repayable in one year or less, or on demand**

As at 30-Sep-15	
Secured	Unsecured
US\$'000	US\$'000
41,321	0

As at 31-Mar-15	
Secured	Unsecured
US\$'000	US\$'000
41,452	0

**Amount repayable after one year**

As at 30-Sep-15	
Secured	Unsecured
US\$'000	US\$'000
243,747	0

As at 31-Mar-15	
Secured	Unsecured
US\$'000	US\$'000
254,320	0

**Details of any collateral**

- (i) The banking facilities of a subsidiary, amounting to approximately US\$5.9 million, granted by two of the banks are secured by corporate guarantees from the Company.
- (ii) The partially drawn mortgage loan facilities of a subsidiary, amounting to approximately US\$42.0 million, is secured by corporate guarantees from the Company and fixed deposit of S\$1.5 million.
- (iii) The finance lease obligations are secured on office equipment with net book values of approximately US\$58,000 (31 March 2015 : US\$71,000).
- (iv) The Company has been granted a US\$39 million credit facilities for the purposes of facilitating cross-border cash management which are secured by pledged deposits of a subsidiary.
- (v) Fixed rate notes of S\$300 million (approximate US\$210 million) issued by a subsidiary under the Group's medium term note programme are guaranteed by the Company.

**1(c) A cash flow statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.**

**Consolidated Statements of Cash Flow for the second quarter and half year ended 30 September 2015**

	<b>The Group</b>			
	<b>2nd Quarter Ended</b>		<b>Half Year Ended</b>	
	<b>30-Sep-15</b>	<b>30-Sep-14</b>	<b>30-Sep-15</b>	<b>30-Sep-14</b>
	US\$'000	US\$'000	US\$'000	US\$'000
<b>Cash Flows from Operating Activities</b>				
Profit before tax	4,583	4,401	15,090	12,927
Adjustments:				
Amortisation of intangible assets	4,996	4,810	10,109	9,705
Realisation of deferred revenue	(1,501)	(1,342)	(3,526)	(3,940)
Bad debts written off	(33)	-	(33)	-
Impairment of property, plant and equipment	-	-	58	(66)
Impairment of intangible assets	-	-	108	-
Depreciation of property, plant and equipment	1,423	1,995	2,840	3,712
Property, plant and equipment written off	(8)	18	7	73
Loss/(gain) on disposal of property, plant and equipment	2	-	7	(1)
Inventories written off	253	122	1,232	317
(Write-back of)/allowance for doubtful trade debts, net	311	(1,206)	(1,108)	(516)
Write-back of doubtful non-trade debts	(2)	(3)	(5)	(6)
Provision for warranty, net	3	12	5	33
(Reversal)/provision for sales return	40	237	(16)	492
Intangible assets written off	-	15	(58)	15
Share-based expenses	1,143	(3,092)	2,145	(1,309)
Inventories write down, net	550	1,607	864	4,078
Interest expenses	3,266	3,454	6,617	6,866
Interest income	(1,825)	(1,815)	(3,871)	(3,546)
Translation differences	(3,441)	(3,728)	(1,839)	(1,225)
<b>Operating cash flows before working capital changes</b>	<b>9,760</b>	<b>5,485</b>	<b>28,626</b>	<b>27,609</b>
(Increase)/Decrease in:				
Inventories	(936)	2,708	(3,382)	(990)
Trade and other receivables	4,970	6,972	10,112	209
Increase/(Decrease) in:				
Trade and other payables	3,205	2,957	(3,042)	5,513
Deferred revenue	1,080	1,509	3,006	3,882
Pension funds	-	(1)	-	77
<b>Cash generated from operations</b>	<b>18,079</b>	<b>19,630</b>	<b>35,320</b>	<b>36,300</b>
Income tax paid, net	(1,997)	(1,776)	(3,582)	(3,406)
Interest income received	1,825	1,815	3,871	3,546
Interest expenses paid	(5,631)	(6,092)	(6,045)	(6,309)
<b>Net cash generated from operating activities</b>	<b>12,276</b>	<b>13,577</b>	<b>29,564</b>	<b>30,131</b>
<b>Cash Flows from Investing Activities</b>				
Purchase of other investments	(1,500)	-	(2,008)	-
Purchase of property, plant and equipment	(709)	(10,726)	(1,172)	(26,273)
Purchase of intangible assets	(2,146)	(2,068)	(4,770)	(3,483)
Proceeds from sale of property, plant and equipment	58	23	196	24
<b>Net cash used in investing activities</b>	<b>(4,297)</b>	<b>(12,771)</b>	<b>(7,754)</b>	<b>(29,732)</b>
<b>Cash Flows from Financing Activities</b>				
Repayment of finance leases	(9)	52	(12)	52
(Payment)/proceeds from long-term bank borrowings	(592)	6,827	(1,206)	17,904
Proceeds from issuance of new shares	960	181	1,492	779
<b>Net cash generated from financing activities</b>	<b>359</b>	<b>7,060</b>	<b>274</b>	<b>18,735</b>
<b>Net increase in cash and cash equivalents</b>	<b>8,338</b>	<b>7,866</b>	<b>22,084</b>	<b>19,134</b>
<b>Cash and cash equivalents at beginning of the period</b>	<b>536,477</b>	<b>531,253</b>	<b>518,253</b>	<b>511,788</b>
<b>Net effect of exchange rate changes on cash and cash equivalents</b>	<b>(21,129)</b>	<b>(13,247)</b>	<b>(16,651)</b>	<b>(5,050)</b>
<b>Cash and cash equivalents at end of the period (Note A)</b>	<b>523,686</b>	<b>525,872</b>	<b>523,686</b>	<b>525,872</b>

**Note to the consolidated statements of cash flows:**

**A. Cash and cash equivalents**

Cash and cash equivalents consist of cash and bank balances, fixed deposits and money markets deposits. Cash and cash equivalents included in the consolidated statements of cash flows comprise the following balance sheet amounts:

	The Group			
	2nd Quarter Ended		Half Year Ended	
	<u>30-Sep-15</u>	<u>30-Sep-14</u>	<u>30-Sep-15</u>	<u>30-Sep-14</u>
	US\$'000	US\$'000	US\$'000	US\$'000
Cash and bank balances	134,204	290,920	134,204	290,920
Fixed deposits	358,494	221,427	358,494	221,427
Money markets deposits	30,988	13,525	30,988	13,525
	<u>523,686</u>	<u>525,872</u>	<u>523,686</u>	<u>525,872</u>



1(d) (i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

**Statement of changes in equity for the second quarter and half year ended 30 September 2015**

	Attributable to equity holders of the Company						Total Equity
	Share Capital	Share Premium	Treasury Shares	Translation Reserves	Other Reserves	Accumulated Profit	
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
<b>The Group</b>							
<b>At 1 April 2015</b>	117	746,042	(54,692)	45,627	19,525	257,807	1,014,426
Profit net of tax	-	-	-	-	-	13,471	13,471
Exchange differences on translation of financial statements of foreign subsidiaries	-	-	-	(32,549)	-	-	(32,549)
<b>Total comprehensive income</b>	-	-	-	<b>(32,549)</b>	-	<b>13,471</b>	<b>(19,078)</b>
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	1 *	1,492	-	-	-	-	1,493
Transfer of reserve pursuant to the exercise of share options	-	2,732	-	-	(2,732)	-	-
Share-based expenses	-	-	-	-	2,144	-	2,144
<b>Total contributions by and distributions to owners</b>	<b>1</b>	<b>4,224</b>	-	-	<b>(588)</b>	-	<b>3,637</b>
<b>At 30 September 2015</b>	<b>118</b>	<b>750,266</b>	<b>(54,692)</b>	<b>13,078</b>	<b>18,937</b>	<b>271,278</b>	<b>998,985</b>
<b>At 1 April 2014</b>	117	740,034	(48,792)	50,839	27,327	483,520	1,253,045
Profit net of tax	-	-	-	-	-	14,794	14,794
Exchange differences on translation of financial statements of foreign subsidiaries	-	-	-	(2,058)	-	-	(2,058)
<b>Total comprehensive income</b>	-	-	-	<b>(2,058)</b>	-	<b>14,794</b>	<b>12,736</b>
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	- *	779	-	-	-	-	779
Transfer of reserve pursuant to the exercise of share options	-	300	-	-	(300)	-	-
Share-based expenses	-	-	-	-	(1,309)	-	(1,309)
<b>Total contributions by and distributions to owners</b>	-	<b>1,079</b>	-	-	<b>(1,609)</b>	-	<b>(530)</b>
<b>At 30 September 2014</b>	<b>117</b>	<b>741,113</b>	<b>(48,792)</b>	<b>48,781</b>	<b>25,718</b>	<b>498,314</b>	<b>1,265,251</b>

Footnote

\* Amounts are less than US\$1,000.

**Statement of changes in equity for the second quarter and half year ended 30 September 2015**

	Attributable to equity holders of the Company						Total Equity
	Share Capital	Share Premium	Treasury Shares	Translation Reserves	Other Reserves	Accumulated Profit	
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
<b>The Company</b>							
<b>At 1 April 2015</b>	117	746,042	(54,692)	-	18,479	67,676	777,622
Profit net of tax representing total comprehensive income	-	-	-	-	-	9,373	9,373
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	1 *	1,492	-	-	-	-	1,493
Transfer of reserve pursuant to the exercise of share options	-	2,732	-	-	(2,732)	-	-
Share-based expenses	-	-	-	-	2,144	-	2,144
<b>Total contributions by and distribution to owners</b>	<b>1</b>	<b>4,224</b>	<b>-</b>	<b>-</b>	<b>(588)</b>	<b>-</b>	<b>3,637</b>
<b>At 30 September 2015</b>	<b>118</b>	<b>750,266</b>	<b>(54,692)</b>	<b>-</b>	<b>17,891</b>	<b>77,049</b>	<b>790,632</b>
<b>At 1 April 2014</b>	117	740,034	(48,792)	-	26,822	55,474	773,655
Profit net of tax representing total comprehensive income	-	-	-	-	-	15,400	15,400
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	- *	779	-	-	-	-	779
Transfer of reserve pursuant to the exercise of share options	-	300	-	-	(300)	-	-
Share-based expenses	-	-	-	-	(1,309)	-	(1,309)
<b>Total contributions by and distribution to owners</b>	<b>-</b>	<b>1,079</b>	<b>-</b>	<b>-</b>	<b>(1,609)</b>	<b>-</b>	<b>(530)</b>
<b>At 30 September 2014</b>	<b>117</b>	<b>741,113</b>	<b>(48,792)</b>	<b>-</b>	<b>25,213</b>	<b>70,874</b>	<b>788,525</b>

Footnote

\* Amounts are less than US\$1,000.

**Note to the Statement of Changes in Equity**

Other reserves consist of the following:

	The Group		The Company	
	30-Sep-15	30-Sep-14	30-Sep-15	30-Sep-14
	US\$'000	US\$'000	US\$'000	US\$'000
Employee share options reserve	12,712	20,034	12,712	20,034
Statutory reserve	1,046	505	-	-
Capital reserves	1,561	1,561	1,561	1,561
Equity component of convertible notes	3,618	3,618	3,618	3,618
	<u>18,937</u>	<u>25,718</u>	<u>17,891</u>	<u>25,213</u>

- 1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

**A. Changes in share capital**

For the quarter ended 30 September 2015, the Company issued 4,000,000 and 500,250 new ordinary shares of par value 1/150 US cent each pursuant to the exercise of options and Performance Share Plan respectively. The issued ordinary shares (excluding treasury shares) increased from 1,684,049,715 shares as at 30 June 2015 to 1,688,549,965 shares of par value 1/150 US cent each at the end of the quarter ended 30 September 2015.

**B. Stock options and performance shares outstanding**

As at 30 September 2015, options in respect of a total of 34,519,193 (31 March 2015: 31,665,213) ordinary shares of par value 1/150 US cent each and 4,390,000 (31 March 2015: 8,000,000) performance shares pursuant to Biosensors Performance Share Plan were outstanding.

- 1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.**

	As at <u>30-Sep-15</u>	As at <u>31-Mar-15</u>
	'000	'000
Total number of issued shares	1,767,212	1,759,368
Less number of shares held as treasury shares	<u>(78,662)</u>	<u>(78,662)</u>
Number of shares in issue excluding treasury shares of the Issuer at end of period	<u><u>1,688,550</u></u>	<u><u>1,680,706</u></u>

- 1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

	Number of Treasury Shares '000
Balance as at 1 April 2015 and 30 September 2015	<u><u>78,662</u></u>

- 2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

The figures have not been audited nor reviewed by the auditors.

- 3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter).**

Not applicable.

- 4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.**

The Group has applied the same accounting policies and methods of computation in the financial statements for the current reporting period as in the audited financial statements for the financial year ended 31 March 2015 except for the adoption of new/revised IFRSs and IFRIC Interpretations that are effective for annual periods beginning on or after 1 April 2015.

- 5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.**

The Group adopted the new/revised IFRSs and IFRIC Interpretations that are effective for annual periods beginning on or after 1 April 2015. Changes to the Group's accounting policies have been made as required, in accordance with the transitional provisions in the respective IFRSs and IFRIC Interpretations.

The following are the new or amended IFRSs that are relevant to the Group:	Effective date
Amendments to IAS 19 – Defined Benefit Plans: Employee Contributions	1 July 2014
IFRS 2 – Share-based Payments	1 July 2014
IFRS 3 – Business Combinations	1 July 2014
IFRS 8 – Operating Segments	1 July 2014
IAS 16 – Property, Plant and Equipment and IAS 38 – Intangible Assets	1 July 2014
IAS 24 – Related Party Disclosures	1 July 2014
IFRS 13 – Fair Value Measurement	1 July 2014

The adoption of the above IFRSs and IFRIC interpretations do not have any significant impact on the financial statements of the Group.

**6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.**

	<u>2nd Quarter Ended</u>		<u>Half Year Ended</u>	
	<u>30-Sep-15</u>	<u>30-Sep-14</u>	<u>30-Sep-15</u>	<u>30-Sep-14</u>
Earnings per ordinary share of the Group:-	US cent	US cent	US cent	US cent
(a) Based on the weighted average number of ordinary shares; and	1			
- Before exceptional items	0.43	0.26	1.04	0.84
- After exceptional items	0.24	0.29	0.80	0.87
(b) On a fully diluted basis	2			
- Before exceptional items	0.43	0.26	1.03	0.84
- After exceptional items	0.24	0.29	0.80	0.86
<sup>1</sup> Weighted average ordinary shares issued ('000)	<u>1,685,808</u>	<u>1,698,679</u>	<u>1,683,710</u>	<u>1,698,060</u>
<sup>2</sup> Weighted average ordinary shares and equivalents outstanding ('000)	<u>1,688,277</u>	<u>1,709,701</u>	<u>1,686,519</u>	<u>1,710,438</u>

Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares.

Diluted earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period, excluding ordinary shares purchased by the Company and held as treasury shares, adjusted for the effects of dilutive options.

**7. Net asset value (for the issuer and group) per ordinary share based on issued share capital of the issuer at the end of the:-**

**(a) current financial period reported on; and  
(b) immediately preceding financial year.**

	<u>As at 30-Sep-15</u>	<u>As at 31-Mar-15</u>
	US cent	US cent
Net assets per ordinary share		
-Group	59.16	60.36
-Company	46.82	46.27
Number of shares in issue at end of period ('000)	<u>1,688,550</u>	<u>1,680,706</u>

Net assets per share is calculated by dividing the net assets by the number of ordinary shares in issue as at the balance sheet date.

**8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must include a discussion of the following:-**

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**  
**(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

**Financial Review for the second quarter and half year ended 30 September 2015**

**Overview:**

In Q2 FY16, the Company continued to see positive impact from its cost reduction strategies. Despite lower revenues, its operating income excluding licensing and royalty revenue grew strongly by 25% year-over-year. On the revenue front, the Company's performance for the quarter was still dragged down by weak licensing revenue, negative FX, as well as soft sales in China.

**Revenue:**

Total revenue, including licensing and royalty revenue, for the quarter decreased 20% to US\$60.0 million from US\$74.8 million in the previous year's corresponding quarter. Total product revenue for the quarter ended 30 September 2015 was US\$56.7 million, compared to US\$68.9 million recorded in the previous year's corresponding quarter. The cardiac diagnostic revenue remained stable at US\$3.7 million, compared to US\$3.9 million in the same quarter of last year. Interventional Cardiology product revenue fell to US\$49.0 million from US\$61.3 million in the same quarter last year. Critical care product revenue increased slightly to US\$4.0 million from the US\$3.7 million in the same quarter last year.

For the half year ended 30 September 2015, total product revenue decreased 16% to US\$117.2 million from US\$139.3 million in the previous year's corresponding period, contributed mainly by reduced revenue in the interventional cardiology business unit as a result of market competition and pricing pressure. The decrease in licensing revenue and royalties for the half financial year ended 30 September 2015 was due to a reduction in the licensee's DES sales in Japan, consequentially total revenue including licensing and royalty revenue decreased 18% to US\$127.0 million from US\$155.0 million in the previous year's corresponding period.

The table below shows the Group's revenue and the principal components of the revenue, as a percentage of total revenue, for the periods indicated:

<u>Revenue by business segments - 2nd Quarter</u>	<u>Q2 FY 2016</u>	<u>%</u>	<u>Q2 FY 2015</u>	<u>%</u>
	<u>US\$'000</u>		<u>US\$'000</u>	
Critical care	3,988	7%	3,655	5%
Interventional cardiology	49,038	82%	61,303	82%
Cardiac diagnostic	3,678	6%	3,906	5%
Total product revenue	56,704	95%	68,864	92%
Licensing and royalties revenue	3,306	5%	5,922	8%
Total revenue	60,010	100%	74,786	100%

<u>Revenue by business segments - First Half Year</u>	<u>H1 FY 2016</u>	<u>%</u>	<u>H1 FY 2015</u>	<u>%</u>
	<u>US\$'000</u>		<u>US\$'000</u>	
Critical care	7,744	6%	8,031	5%
Interventional cardiology	102,542	81%	122,998	80%
Cardiac diagnostic	6,950	5%	8,303	5%
Total product revenue	117,236	92%	139,332	90%
Licensing and royalties revenue	9,801	8%	15,664	10%
Total revenue	127,037	100%	154,996	100%

#### **Cost of sales and gross profit:**

Overall gross margin for products was 69% for the quarter ended 30 September 2015, compared to 70% for the previous year's corresponding quarter. This was attributable mainly to lower gross profit margins from the distribution activities of Nobori stents in Japan and the price reductions in various geographic regions.

Overall gross margin for products in the half year ended 30 September 2015 was 71%, compared to 70% for the previous year's corresponding period.

The table below shows the Group's gross profit by business segments, as a percentage of segment revenue, for the periods indicated:

<u>Gross profit by business segments - 2nd Quarter</u>	<u>Q2 FY 2016</u>	<u>Gross Margin</u>	<u>Q2 FY 2015</u>	<u>Gross Margin</u>
	<u>US\$'000</u>	<u>%</u>	<u>US\$'000</u>	<u>%</u>
Critical care	1,769	44%	1,579	43%
Interventional cardiology	35,353	72%	43,963	72%
Cardiac diagnostic	1,820	49%	2,436	62%
Total product gross profit	38,942	69%	47,978	70%
Licensing and royalties revenue	3,306	100%	5,922	100%
Total gross profit	42,248	70%	53,900	72%

<u>Gross profit by business segments - First Half Year</u>	<u>H1 FY 2016</u>	<u>Gross Margin</u>	<u>H1 FY 2015</u>	<u>Gross Margin</u>
	<u>US\$'000</u>	<u>%</u>	<u>US\$'000</u>	<u>%</u>
Critical care	3,406	44%	3,487	43%
Interventional cardiology	75,845	74%	89,582	73%
Cardiac diagnostic	4,224	61%	4,897	59%
Total product gross profit	83,475	71%	97,966	70%
Licensing and royalties revenue	9,801	100%	15,664	100%
Total gross profit	93,276	73%	113,630	73%

#### **Operating expenses:**

The Group's total operating expenses for the second quarter were US\$33.5 million compared to US\$43.7 million for the second quarter in the previous year. Total operating expenses as a percentage of product revenue for the quarter was 59%, compared to 63% in the previous year same quarter. For the half year ended 30 September 2015, total operating expenses were US\$66.3 million compared to US\$88.3 million in the previous year's half year.

(i) Sales and marketing expenses

Sales and marketing expenses decreased 23% to US\$19.9 million for the quarter ended 30 September 2015 compared to US\$26.0 million for the quarter ended 30 September 2014. For the half year ended 30 September 2015, the sales and marketing expenses were US\$40.2 million, comparing to US\$52.9 million in the corresponding period of last year. The decrease was the result from reduced payroll related expenses, marketing, exhibition and travelling related expenses.

(ii) General and administrative expenses

General and administrative expenses were US\$8.1 million for the quarter ended 30 September 2015 compared to US\$9.5 million in the previous year's corresponding quarter, a decrease of 15%. For the half year ended 30 September 2015, compared to the corresponding period for last year, general and administrative expenses reduced to US\$15.9 million from US\$20.1 million. The decrease for the period was mainly due to decreased professional fee and share-based payment expenses.

(iii) Research and development expenses

Research and development expenses decreased 32% to US\$5.6 million for the quarter ended 30 September 2015 compared to US\$8.3 million in the quarter ended 30 September 2014. For the half year ended 30 September 2015, the research and development expenses were US\$10.2 million compared to US\$15.3 million for the same period in prior year. The decrease was mainly due to lower clinical trial expenses.

(iv) Other operating income/(expenses)

Other operating expenses for the quarter was mainly the exchange gain from the appreciation of JPY and EUR against USD during the period.

**Income tax**

Income tax for the current quarter ended 30 September 2015 includes mainly corporate income tax expenses.

**Net result after tax:**

The net result for the quarter ended 30 September 2015 was a net profit after tax of US\$4.01 million as compared to a net profit after tax of US\$4.92 million for the same quarter in the previous year. The reduction was due to lower product and licensing revenue.

For the half year under review, the Group recorded a net profit after tax of US\$13.5 million compared to a net profit after tax of US\$14.8 million in the prior year's period. The reduction was due to lower product and licensing revenue.

**Use of proceeds from the issue of 4.875% fixed rate notes due 2017**

The Company refers to its announcement on 23 January 2013 in relation to the issuance of an aggregate of S\$300 million (approximate US\$222 million) in principal amount of 4-year notes with interest at a rate of 4.875%, payable semi-annually in arrear.

As at 30 September 2015, out of the total net proceeds of S\$295.4 million (approximate US\$206.7 million) from the issuance of 4-year notes, the Company paid US\$86.7 million for the acquisition of the business of Spectrum Dynamics, technical know-how of DES and other unquoted investments.

The Company will continue to make periodic announcements on the utilisation of the proceeds from the notes issue as and when such proceeds are materially deployed.

**9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

Not Applicable.

**10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

Although we have seen improvement in the company's operating income for the quarter and first half of the fiscal year as the result of continuous operating efficiency enhancement, however moving forward there are still a lot of market uncertainty including but not limited continuous ASP erosion, China overall market weakness, uncertainty of FX impact as well as our Japan sales transforming from licensing sales from Terumo to company's direct sales of BMX-J stents. Meanwhile the Company is working toward taking necessary steps to mitigate these risks.

Recently, Biosensors and CITIC Private Equity (CITIC PE), a substantial shareholder of the Company, have jointly announced an amalgamation agreement in which, if approved by shareholders according to SGX rules, Biosensors will become a privately owned company and be delisted from SGX.

**11. Dividend**

**(a) Current Financial Period Reported On**

Any dividend declared for the current financial period reported on? None

**(b) Corresponding Period of the Immediately Preceding Financial Year**

Any dividend declared for the corresponding period of the immediately preceding financial year? None

**(c) Date payable**

Not applicable.

**(d) Books closure date**

Not applicable.

**12. If no dividend has been declared/recommended, a statement to that effect.**

No dividend has been declared or recommended during the period under review.

**13. Interested person transactions**

There were no new interested person transactions during the second quarter ended 30 September 2015 under Chapter 9 of the Listing Manual.

**BY ORDER OF THE BOARD**

**Yoh-Chie Lu**  
**Chairman**  
**3 March 2016**



**Statement by Directors**  
**Pursuant to SGX Listing Rule 705(4)**

In the opinion of management, the accompanying unaudited consolidated interim financial statements have been prepared on a consistent basis with the March 31, 2015 audited consolidated financial statements. The unaudited consolidated financial statements are presented in accordance with International Financial Reporting Standards ("IFRS"). The preparation of consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods, and therefore the actual results may differ from those estimates. The consolidated interim financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto included in our FY 2014/15 annual report.

To the best of our knowledge, nothing has come to the attention of the Directors which may render the interim financial results to be false or misleading. Based on our knowledge, the financial statements and other financial information included in this report, present fairly in all material respects the financial conditions, results of operations and cash flows of the Group as of, and for, the periods presented in this announcement.

**On Behalf of the Board**

**Yoh-Chie Lu**  
**Chairman**

**Jose Calle Gordo**  
**CEO**

**3 March 2016**

**BIOSENSORS INTERNATIONAL GROUP, LTD.**

Registered Address : Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda

Mailing Address : 36 Jalan Tukang, Singapore 619266

[www.biosensors.com](http://www.biosensors.com)